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Plasma von-Willebrand factor levels predict in – hospital survival in patients 
with acute on chronic liver failure 
 
Abstract :  
Background and Aims : Circulating levels of von Willebrand factor (vWF) predict mortality in 
patients with cirrhosis. We hypothesised that systemic inflammation in acute on chronic liver 
failure (ACLF) will stimulate endothelium, increase vWF levels and promote platelet 
microthombi causing organ failure.  
Methods : In this prospective study, we correlated plasma vWF levels with organ failure, liver 
disease severity, sepsis and systemic inflammatory response syndrome (SIRS) and also analysed 
if vWF levels predicted in-hospital composite poor outcome (i.e. death/discharged in terminal 
condition/liver transplantation) in consecutive ACLF patients.  
Results : 21of the 50 ACLF patients studied, had composite poor outcome.  ACLF patients had 
markedly elevated vWF antigen and activity (7 fold and 5 fold median increase, respectively) on 
Days 1 and 3. Median ratio of vWF to ADAMTS13 activity on Day 1 was significantly higher in 
ACLF patients (11.2) compared to 20 compensated cirrhosis patients (3.3) and healthy 
volunteers (0.9). On Day 1, AUROC to predict composite poor outcome of hospital stay for 
ACLF patients for vWF antigen, vWF activity and MELD score were 0.63, 0.68 and 0.74, 
respectively. vWF activity correlated better with liver disease severity (MELD score, ACLF 
grade) and organ failure (SOFA score) than vWF antigen; in contrast, neither vWF antigen nor 
activity correlated with platelet count, sepsis or SIRS.  
Conclusions: vWF levels are markedly elevated, correlate with organ failure and predict in–
hospital survival in ACLF patients.  This data provides a mechanistic basis for postulating that 
vWF-reducing treatments such as plasma exchange may benefit ACLF patients. 
Keywords.:  ACLF, endothelial activation, vWF, ADAMTS13  
 
 
Introduction 
Acute on chronic liver failure (ACLF) is associated with high (50-90%) short and medium - term 
mortality[1]. Increasing grade of ACLF (ie: increasing numbers of organs failing)[2] is a strong 
predictor of short term mortality[3]. The high mortality in ACLF is mainly attributed to 
unregulated systemic inflammation, causing (both hepatic and extra-hepatic) organ failure[2,4].  
Presence of systemic inflammatory response syndrome (SIRS) predicts development of ACLF in 
patients with alcoholic liver disease[5]. 
In critically ill patients, SIRS contributes to disseminated intravascular coagulation, development 
of microvascular thrombosis (varying from 20% to 100% depending on the organ studied) and 
consequent multi-organ failure [6]. von Willebrand factor (vWF), released from activated 
endothelium in very high molecular weight forms, is an adhesive protein to which platelets stick. 
In patients with sepsis, development of organ failure and systemic inflammation is linked to 
imbalance of vWF – ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 
1 motif, member 13) : high vWF levels and low levels of ADAMTS13 (a vWF cleaving 
protease)[7]. A typical example is complicated malaria, where in thrombocytopenic patients, 
vWF - ADAMTS13 imbalance maybe the pathogenic mechanism linking inflammation to 
microvascular occlusion[8]. vWF levels also predict 28 day mortality in ICU patients with 
SIRS[9]. 
Similar vWF – ADAMTS13 imbalance occurs in cirrhosis, acute liver failure and when systemic 
inflammation is superimposed on cirrhosis. In patients with cirrhosis (of varied etiology, 
including viral and alcohol), vWF levels correlate with hepatic fibrosis[10], hepatic vein pressure 
gradient[10-12], and predict survival over next 2 - 3 years[11,12]. In acute liver failure, vWF-
ADAMTS13 imbalance predicts survival[13]. vWF levels predict survival in patients with 
systemic inflammation superimposed on cirrhosis[14]. In addition, vWF-ADAMTS13 imbalance 
is noted in acute alcoholic hepatitis[15].  
Although there is an increase in vWF levels in patients with cirrhosis, there may not be a 
commensurate increase in the vWF activity. This, hitherto unexplained phenomenon, may be one 
of the body’s mechanisms to limit propensity of widespread thrombotic events in these 
patients[13]. ADAMTS13 regulates vWF multimer fraction, limiting the biological activity of 
vWF, and a decrease in ADAMTS13 concentration and activity may exacerbate the imbalance. 
Role of other vWF cleaving proteases in health and disease has not been well studied[13].  
 
We hypothesized that systemic inflammation in ACLF will further activate the endothelium and  
elevate plasma vWF levels,  increase platelet microthombi formation in affected organs, reduce 
organ perfusion and potentiate organ failure.  
Prognostic significance of vWF levels in ACLF has not been studied.  
The objectives of this study were  
1. To document plasma vWF levels and correlate these with organ failure, liver disease 
severity, sepsis and SIRS in ACLF patients.  
2. To analyse plasma vWF levels as predictors of in – hospital survival in ACLF patients.  
3. To compare plasma vWF – ADAMTS13 balance in ACLF patients; in compensated 
cirrhosis patients, who did not have ACLF; and in healthy volunteers.  
 
Materials and Methods : 
From October 2014 to March 2015, consecutive adult patients with presentation as ACLF (as per 
APASL definition)[16], admitted in our department were prospectively recruited for this study 
after obtaining their informed consent.  
Patients with hepatocellular carcinoma or portal vein thrombosis and those unwilling to 
participate were excluded from this study. Pregnant women and children were also excluded. 
All patients underwent routine clinical examination and laboratory assessment. Underlying 
chronic liver disease was diagnosed based on clinical, biochemical, radiological and/or 
histological features. Assessment for causes of acute hepatic insult and of underlying chronic 
liver disease (e.g. alcohol, hepatotropic viruses, use of hepatotoxic drugs, autoimmune hepatitis, 
etc.) was done.  
Assays for plasma von Willebrand factor : As per pre-specified study protocol, all study patients 
underwent assays for plasma vWF antigen and activity on Day 1 and Day 3 of hospital stay. For 
vWF assays, blood was collected using 0.109 M citrate anticoagulant and centrifuged at 2500 g 
for 15 minutes at 4⁰C. The separated plasma were aliquoted and stored frozen at - 80⁰C until 
assay. 
vWF antigen was measured using an ELISA kit (quantitative ELISA) as per manufacturer’s 
instructions (Zymutest vWF Cat #RK 030A Hyphen BioMed, France). Collagen binding activity 
of vWF was measured by a similar method (Zymutest vWF:CBA Cat #RK 038A Hyphen 
BioMed, France) using microwells coated with fibrillar collagen types I and III[17]. A second 
order polynomial standard curve was used to obtain vWF antigen level as well as activity.  In 
patients with high vWF levels, samples were pre-diluted (1 in 10) for the assays.  Normal values 
for both plasma vWF antigen and activity were 50 % to 160 %.  Specific vWF activity was 
calculated as ratio of vWF activity : vWF antigen. 
Assay for plasma ADAMTS13 activity : 
ADAMTS13 activity was estimated on Day 1 in all ACLF study patients on citrated platelet-poor 
plasma by an in-house collagen binding assay as previously described[18].  Normal range of 
ADAMTS13 activity was 55%-160%. 
Plasma vWF – ADAMTS13 balance in ACLF, compensated cirrhosis and healthy volunteers : 
We compared vWF – ADAMTS13 balance in ACLF patients, patients with Hepatitis B / C 
related compensated cirrhosis (none were in ACLF as per APASL criteria[16]) and in healthy 
volunteers. vWF:ADAMTS13 ratio was calculated by dividing Day 1 vWF activity by Day 1 
ADAMTS13 activity.  
Assessment of organ failure, liver disease severity, sepsis and SIRS in ACLF patients :  
Sequential organ failure (SOFA) score[19] (to assess organ failure), model for end-stage liver 
disease (MELD) score and ACLF grade (as per EASL-CLIF (Chronic Liver Failure) consortium 
definition) (to assess liver disease severity) were calculated on Day 1 of hospital stay.  Presence 
of SIRS[20]and sepsis[21] was assessed as per standard definition. 
 Incidence of new onset acute kidney injury and/or hepatic encephalopathy was documented on a 
daily basis during hospitalization. 
Follow up and study outcome parameters in ACLF patients : All ACLF patients received 
standard medical treatment (no patient was treated with plasma exchange or N-acetyl cysteine) 
and were followed up daily. Study outcome (in-hospital transplant-free survival) was classified 
as discharge from hospital alive (in stable condition) or composite poor outcome (death / 
discharge in terminal condition / liver transplant).  
Statistical analysis : Continuous variables were expressed as mean with standard deviation or 
median with range. Discrete variables were expressed as numbers and percentage. Continuous 
variables were compared by Mann Whitney U test / Wilcoxon sign rank and discrete variables by 
chi square test or Fischer’s exact test, as relevant. Bi-variate correlation was assessed by 
Spearman correlation coefficient. Multivariate logistic regression was done to assess independent 
factors affecting survival in patients with ACLF. Univariate ordinal regression was done to 
analyse the ability of variables to predict baseline grade of ACLF (as per EASL-CLIF grading). 
Receiver operating characteristic (ROC) curve was used to assess sensitivity and specificity of 
plasma vWF as predictor of composite poor outcome.  Assuming a 30% mortality rate in patients 
admitted to hospital with ACLF (audit estimates), we calculated that a sample size of 50 patients 
would allow us to evaluate role of vWF as a predictor, independent of MELD score, of in-
hospital mortality. SPSS version 15 was used for statistical analysis and a two-sided p-value of 
<0.05 was considered as significant.  
The study was approved by the institutional review board and ethics committee.  
 
Results 
Of the 50 ACLF patients studied, 29 (58%) were discharged in a stable condition while 21 (42%) 
had composite poor outcome - 10 died (hospital stay: 7, 2-12 days), 9 were discharged in 
terminal condition (hospital stay: 6, 2-11 days) and 2 underwent liver transplantation (hospital 
stay prior to transplant: 8, 5-11 days).   
Baseline demographics and relevant laboratory data are depicted in Table 1. All ACLF study 
patients were in Child’s class C at admission. Alcohol was the most common cause of chronic 
damage and of acute insult in ACLF patients. Other causes of chronic liver damage were - 
hepatitis B (5), cryptogenic (3), autoimmune (2) and non-alcoholic fatty liver disease (1). Other 
causes of acute insult were cryptogenic (6), hepatitis E (3), autoimmune flare (2), hepatitis B (1) 
and swine flu (1). 
With increasing ACLF grade on Day 1 of hospital stay, MELD score as well as the proportion of 
patients with composite poor outcome increased (Table 2). New onset renal failure / 
encephalopathy were more common in ACLF patients with composite poor outcome (n=7) when 
compared to patients who were discharged in a stable state (n=2; p-value : 0.025).  
 
Plasma vWF level on Day 1 of hospital stay (Figure 1) : 
Day 1 plasma vWF antigen (725%, 212%-1347%; median, range) and activity (534%, 97%-
1157%) were elevated in 50 ACLF patients studied. Day 1 plasma vWF antigen was higher in 
patients with composite poor outcome (742%, 264%-1347%) when compared to patients 
discharged in stable condition (699%, 212%-1249%; p-value: 0.135).  Day 1 plasma vWF 
activity was also significantly higher in patients with composite poor outcome (632%, 119%-
1157%) when compared to patients discharged in stable condition (490% , 97%-986%; p-value : 
0.025). 
 
Plasma vWF level on Day 3 of hospital stay : 
Day 3 plasma vWF antigen and activity remained elevated (712%, 279%-1411%; median range 
and 475%, 100%-1304% respectively) in 42 ACLF patients studied. There was no difference in 
plasma vWF antigen (746%, 326%-1157% v/s 689%, 279%-1411%; p-value : 0.6) and activity 
(457%, 244%-1334% v/s 497%, 100%-1304%; p-value : 0.916) in patients with composite poor 
outcome compared to those discharged in stable condition. 
The interval change in plasma vWF antigen and activity over 3 days (Day 1 to Day 3 of hospital 
stay) was not significantly different in patients with composite poor outcome as compared to 
patients discharged in stable condition.  
 
Correlation of Day 1 plasma vWF level with organ failure (SOFA score), liver disease severity 
(MELD score, ACLF grade), sepsis and SIRS in ACLF patients : 
There was a moderate but significant positive correlation of Day 1 SOFA score with Day 1 vWF 
antigen (ρ=0.35; p-value : 0.02) and with Day 1 vWF activity (ρ=0.4; p-value : 0.002). There 
was a moderate, but significant positive correlation of Day 1 MELD score with Day 1 vWF 
antigen (ρ=0.25; p-value : 0.09) and also with Day 1 vWF activity (ρ=0.31; p-value : 0.03).  
With increasing grade of ACLF on Day 1, there was a trend to increase in Day 1 vWF antigen 
and significant increase in Day 1 vWF activity. (Table 2) 
Neither vWF antigen nor activity showed any correlation with baseline SIRS / sepsis nor with 
new onset kidney injury and hepatic encephalopathy (Table 3).  Neither vWF antigen nor activity 
on Day 1 had any significant correlation with platelet counts, nor with alcohol as an etiology of 
acute insult (data not shown).  
vWF antigen showed excellent and statistically significant correlation with vWF activity in all 
ACLF patients (ρ=0.85; p-value : <0.001), and also in ACLF patients with SIRS (ρ=0.84; p-
value : <0.001) 
 
Plasma vWF level as predictor of in-hospital survival : 
On multivariate logistic regression analysis, adjusting for MELD score, Day 1 vWF activity 
showed a trend towards prediction of composite poor outcome [adjusted hazard ratio :  1.002; 
95% CI: 1-1.005; p-value : 0.1]. 
Area under ROC curve (AUROC) for Day 1 plasma vWF antigen to predict composite poor 
outcome of hospital stay was 0.63 (95% CI: 0.47-0.8) and for vWF activity was 0.68 (95% CI: 
0.52-0.84). AUROC for Day 1 MELD score and SOFA score to predict composite poor outcome 
was 0.74 (95% CI: 0.6-0.89) and 0.72 (95% C.I: 0.6-0.8) respectively. There was no statistical 
difference between AUROC of MELD score and vWF activity to predict composite poor 
outcome (p-value : 0.4). For Day 1 vWF activity the optimal cutoff for predicting composite 
poor outcome, as disclosed by Youden index, was 712% (sensitivity: 48% and specificity: 86%). 
Table 4 describes the sensitivity, specificity, predictive values and likelihood ratios for various 
cut-offs of Day 1 vWF activity in predicting in - hospital survival.  
 
Correlation of day 1 plasma ADAMTS13 activity with in-hospital survival in ACLF patients : 
Day 1 ADAMTS13 activity was similar in ACLF patients with composite poor outcome (n=21, 
42%,11%-120%; median, range) and in ACLF patients who were discharged in stable condition 
(n=29, 58%, 16%-125%; p-value: 0.11). There was a significantly higher day 1 
vWF:ADAMTS13 activity ratio  in ACLF patients with composite poor outcome (19, 1.4 – 96.4) 
as compared to patients who were discharged in stable state (8.5, 1.2 – 42.9; p-value : 0.03). 
 
Plasma vWF-ADAMTS13 balance in ACLF patients as compared to compensated cirrhosis 
patients and healthy volunteers : 
Figure 2 reflects the vWF antigen and activity in ACLF patients as compared 20 patients with 
compensated cirrhosis (age : 47 years, 23-64 years ; male : 14; hepatitis B related : 10 patients, 
hepatitis C related : 10 patients ; Child’s class: A-9, B-5, C-5; MELD score: 10, 7-24)   and 19 
healthy volunteers (age:33 years, 27-65 years; median, range; male:16). 
vWF antigen in ACLF patients (725 %, 212%-1347%; median, range) was significantly higher 
than in patients with Hepatitis B / C related cirrhosis (332%, 81%-785%) and in healthy 
volunteers (85%, 46%-128%; p-value < 0.001).    
Similarly vWF activity was significantly higher in ACLF patients (534%, 97%-1157%) as 
compared patients with Hepatitis B / C related cirrhosis (275%, 80%-860%) and healthy 
volunteers (89%, 45%-130%; p-value < 0.001).    
Specific vWF activity was significantly lower in ACLF patients (0.77, 0.15-1.5; median, range) 
than healthy volunteers (0.98, 0.62-1.9) and patients with compensated cirrhosis (0.9, 0.5-1.2; p-
value < 0.001).  
Day 1 plasma ADAMTS13 activity was significantly lower in 50 ACLF patients (47.5%, 11%-
125%; median, range) as compared to 19 healthy volunteers (98.5%, 55%-122%; p-value<0.001) 
and 20 patients with compensated cirrhosis (96.5%, 27%-127%; p-value < 0.001).  
Ratio of vWF activity: ADAMTS13 activity (on Day 1) was significantly higher in ACLF 
patients (11.2, 1.2-96.4; median, range) as compared to patients with compensated cirrhosis (3.3, 
0.7-28.1, p-value : 0.01) and healthy volunteers (0.9, 0.4-2.4; p-value < 0.001).  
 
Discussion : 
We document markedly elevated plasma vWF antigen (7 fold median increase) and activity (5 
fold median increase) on Day 1 and Day 3 in ACLF patients. vWF antigen and activity levels 
were 2 fold higher in ACLF patients when compared  to compensated cirrhosis patients.  
Of the different vWF assays done in ACLF patients, vWF activity on Day 1 was the best 
predictor of composite poor outcome at the end of hospital stay, with vWF activity level of > 
1000 % having 100% positive predictive value (Table 4).  Similarly, vWF activity on Day 1 
correlated better with liver disease severity (MELD score, ACLF grade) and organ failure 
(SOFA score) on Day 1 than vWF antigen on Day 1; in contrast, neither vWF antigen nor 
activity correlated with platelet count, sepsis or SIRS on Day 1 nor with new onset renal failure 
or hepatic encephalopathy during hospital stay.  
Though all 50 ACLF patients studied had marked elevation of vWF levels, 9 (18%) patients did 
not fulfill criteria for SIRS and 30 (60%) did not have sepsis (Table 3). As APASL criteria for 
ACLF provides definition of ACLF and not disease severity classification, we used three 
different severity scores – MELD score, SOFA score and EASL-CLIF grading to stratify 
patients.  Our study protocol pre-specified composite poor outcome of hospital stay as death/ 
discharged in terminal state/ liver transplant. This was to account for terminally ill patients 
requesting discharge from hospital, which is a reality in many resource constrained settings in 
developing countries. Duration of jaundice and of ‘liver failure’ prior to admission were not 
documented. 
Infusion of endotoxin to human volunteers induced systemic inflammation, thrombocytopenia, 
leukocytosis, high vWF and low ADAMTS13 levels at 4 and 24 hours; and ultra-
large VWF multimers after 4 hours[22]. Similar vWF – ADAMTS13 imbalance occurred after 
Desmopressin infusion in healthy volunteers[23]. Marked elevation of vWF levels in ACLF 
patients in our study probably reflects an ‘acute-on-chronic’ pro-inflammatory milieu leading to 
endothelial activation by release of inflammatory mediators reported in ACLF[1]. As most 
patients with ACLF had SIRS at admission, we failed to demonstrate its correlation with raised 
vWF levels.  
vWF – ADAMTS13 imbalance occurs in patients with advancing cirrhosis[24]; in contrast, this 
imbalance occurs in patients with non cirrhotic intrahepatic portal hypertension (NCIPH), who 
have well preserved liver functions[25,26], suggesting that vWF – ADAMTS13 imbalance 
maybe a  pathogenic mechanism of chronic portal microangiopathy which causes non cirrhotic 
intrahepatic portal hypertension[27].  As NCIPH is often labeled as ‘cryptogenic’ cirrhosis, we 
did not include cryptogenic cirrhosis as a disease control.  
In our study, etiology of ACLF patients (most patients had alcohol as etiology of liver disease) 
was different from patients with compensated cirrhosis (hepatitis B and C related). This is a 
limitation of our study, but previous studies (which included patients with alcohol liver disease) 
have otherwise shown an increase in vWF proportional to disease and portal hypertension 
severity irrespective of the etiology[11,12]. We also did not observe the effect of etiology of 
acute insult (alcohol v/s others) on vWF levels in ACLF study patients. 
Of the many vWF assays tested in patients with liver disease, vWF antigen level is the easiest 
and most commonly performed assay.  N acetyl cysteine used to treat acute liver failure, can be a 
confounder in some vWF assays, as it reduces vWF multimer size and activity[28].   
Increased vWF levels induce further platelet adhesion, despite reduced function of vWF 
molecule in patients with cirrhosis[29]. Specific vWF activity in the current study also shows 
reduced vWF function, despite increased vWF levels in compensated cirrhosis; this phenomenon 
is even more exaggerated in ACLF. This may be secondary to compensatory, but often 
unsuccessful, mechanisms trying to limit the harmful thrombogenic effects of increased vWF. 
Exaggerated platelet aggregation secondary to ultra-large vWF multimers and microvascular 
occlusion could explain the prognostic significance of vWF in cirrhosis[11,12,14,30], in acute 
liver injury[13] and in ACLF (current study). The degree of vWF elevation (Table 5) probably 
reflects degree of endothelial activation and tendency for microvascular occlusion (and hence 
failure) of the liver and other organs affected and probably determines the length of survival in 
these patients.  Based on vWF levels, compared to endothelial ‘activation’ in compensated 
cirrhosis patients, endothelial ‘hyperactivation’ is seen in ACLF patients (Table 5).  
While intrahepatic endothelial activation and microvascular occlusion may impede hepatic 
perfusion and contribute to liver failure and short term mortality in acute liver failure; it leads to 
formation of focal parenchymal extinction lesions and confluent fibrosis in the liver[31] and 
probably contributes to medium term mortality in cirrhosis. In ACLF, it is likely that both these 
processes are superimposed on each other. 
In this study we found significantly reduced ADAMTS13 activity (as measured by collagen 
binding assay) in ACLF patients as compared to compensated cirrhosis and healthy controls. We 
did not estimate ADAMTS13 activity by FRET (fluorescence resonance transfer) to avoid 
confounding by raised serum bilirubin (present in all ACLF patients).  
High vWF levels causing microvascular occlusion by exaggerated platelet adhesion onto 
activated endothelium causing organ failure typically occurs in thrombotic thrombocytopenic 
purpura and hemolytic uremic syndrome[32]. Plasma exchange with fresh frozen plasma 
replacement dramatically reduced mortality in these conditions[33]. Removal of large volumes 
of plasma during plasma exchange non–selectively reduces many plasma proteins including 
vWF[34,35]. ADAMTS13 supplementation is provided by fresh frozen plasma infusion[36]. 
Apart from primary thrombotic microangiopathies[32,33], plasma exchange may also be 
beneficial in  other syndromes associated with thrombocytopenia and vWF–ADAMTS13 
imbalance[8,37-40].  
ACLF (current study) and acute liver failure patients have thrombocytopenia associated with 
vWF-ADAMTS13 imbalance[13]. In hepatitis B related ACLF, addition of plasma exchange 
improved short term survival compared to treatment with nucleoside analogues alone[41-43].  
High volume plasma exchange reduced multi-organ dysfunction and improved transplant free 
survival in acute liver failure patients[44]. vWF reduction (which interrupts excessive platelet 
adhesion, microvascular thrombosis and multi-organ failure) maybe one mechanism by which 
plasma exchange improves survival in ACLF and acute liver failure patients.   
In ACLF and other thrombocytopenic conditions wherein vWF-rich activated endothelium 
entraps more platelets, it is logical to avoid platelet transfusions; when platelet transfusions are 
deemed necessary, it is better to transfuse fresh frozen plasma initially (which supplements  
ADAMTS13) followed by platelet transfusion[45,46].  
Studies exploring the role of vWF in progression of liver disease, by measuring vWF in hepatic 
venous blood and liver tissue can be undertaken. Further studies of plasma vWF levels as a 
prognostic marker of short term mortality in larger number of ACLF patients are needed. Effect 
of plasma exchange and other vWF reducing treatments[47-49] needs to be studied in ACLF and 
in acute liver failure patients. In conclusion, ACLF is characterized by markedly raised plasma 
vWF levels. vWF levels correlate with organ failure, liver disease severity and predicts in–
hospital survival in ACLF patients.  
  
Financial Support :  We gratefully acknowledge funding support received from Department of 
Science and Technology, Government of India (File No. EMR/2015/000570) and FLUID 
research funds, Christian Medical College, Vellore, India  towards the conduct of this study. 
Conflict of Interest: KSP, AG, GJA, AR, KAB, IM, UZ, KGS, EE, CEE declare that they have 
no conflict of interest. 
Ethical approval: The study was performed in a manner to conform with the Helsinki 
Declaration of 1975, as revised in 2000 and 2008 concerning human and animal rights, and the 
authors followed the policy concerning informed consent as shown on Springer.com. 
Informed consent: Informed consent was obtained from all individual participants included in 
the study.  
References: 
1. Jalan R, Gines P, Olson JC, Mookerjee RP, Moreau R, Garcia-Tsao G, et al. Acute-on 
chronic liver failure. J Hepatol. 2012 ; 57 : 1336-48. 
2. Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, et al. CANONIC Study 
Investigators of the EASL–CLIF Consortium. Acute-on-chronic liver failure is a distinct 
syndrome that develops in patients with acute decompensation of cirrhosis. 
Gastroenterology 2013;144:1426-37  
3. Angeli P, Rodríguez E, Piano S, Ariza X, Morando F, Solà E,   et al. CANONIC Study 
Investigators of the EASL-CLIF Consortium. Acute kidney injury and acute-on-chronic 
liver failure classifications in prognosis assessment of patients with acute 
decompensation of cirrhosis. Gut 2015;64:1616-22.  
4. Bajaj JS, O'Leary JG, Reddy KR,  Wong F, Biggins SW, Patton H, et al. North American 
Consortium For The Study Of End-Stage Liver Disease NACSELD. Survival 
in infection-related acute-on-chronic liver failure is defined by extrahepatic organ 
failures. Hepatology. 2014;60:250-6.  
5. Kim HY, Chang Y, Park JY, Ahn H Cho H, Han SJ, et al.  Characterization of acute-on-
chronic liver failure and prediction of mortality in Asian patients with active alcoholism. 
J Gastroenterol Hepatol. 2015. doi: 10.1111/jgh.13084. [Epub ahead of print] 
6. Gando S. Microvascular thrombosis and multiple organ dysfunction syndrome. Crit Care 
Med. 2010;38 (2 Suppl): S35-42.  
7. Claus RA, Bockmeyer CL, Budde U, Kentouche K, Sossdorf M, Hilberg T, et al. 
Variations in the ratio between von Willebrand factor and its cleaving protease during 
systemic inflammation and association with severity and prognosis of organ failure. 
Thromb Haemost. 2009;101:239-47 
8. Schwameis M, Schörgenhofer C, Assinger A, Steiner MM, Jilma B. VWF excess and 
ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis 
in DIC, malaria, and TTP. Thromb Haemost. 2015;113:708-18. 
9. Hyseni A, Kemperman H, de Lange DW, Kesecioglu J, de Groot PG, Roest M. Active 
von Willebrand factor predicts 28-day mortality in patients with systemic inflammatory 
response syndrome. Blood 2014;123:2153-6. 
10. Maieron A, Salzl P, Peck-Radosavljevic M, Trauner M, Hametner S, Schöfl R,  et al. Von 
Willebrand Factor as a new marker for non-invasive assessment of liver fibrosis and 
cirrhosis in patients with chronic hepatitis C. Aliment Pharmacol Ther.2014;39:331-8.  
11. La Mura V, Reverter JC, Flores-Arroyo A, Raffa S, Reverter E, Seijo S, et al. Von 
Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal 
hypertension. Gut 2011;60:1133-8. 
12. Ferlitsch M, Reiberger T, Hoke M, , Salzl P, Schwengerer B, Ulbrich G, et al. von 
Willebrand factor as new noninvasive predictor of portal hypertension, decompensation 
and mortality in patients with liver cirrhosis. Hepatology. 2012 ; 56 : 1439 - 47.  
13. Hugenholtz GC, Adelmeijer J, Meijers JC, Porte RJ, Stravitz RT, Lisman T. An 
unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: 
implications for hemostasis and clinical outcome. Hepatology 2013;58:752-61.  
14. Reuken PA, Kussmann A, Kiehntopf M, Budde U, Stallmach A, Claus RA, et al. 
Imbalance of von Willebrand factor and its cleaving protease ADAMTS13 during 
systemic inflammation superimposed on advanced cirrhosis. Liver Int. 2015;35:37-45. 
15. Uemura M, Fujimura Y, Matsuyama T, Matsumoto M, Ishikawa M, Ishizashi H, Kato S, 
Tsujimoto T, Fujimoto M, Yoshiji H, Morioka C, Fukui H. Potential role of ADAMTS13 
in the progression of alcoholic hepatitis. Curr Drug Abuse Rev 2008;1:188-96 
16. Sarin SK, Kedarisetty CK, Abbas Z, Amarapurkar D, Bihari C, Chan AC,  et al. 
APASL ACLF Working Party. Acute-on-chronic liver failure: consensus 
recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 
2014. Hepatol Int. 2014;8:453-71. 
17. Brown JE, Bosak JO. An Elisa test for the binding of von Willebrand antigen to 
collagen. Thromb Res. 1986;43:303–311. 
18. Gerritsen HE, Turecek PL, Schwarz HP, Lämmle B, Furlan M. Assay of von Willebrand 
factor (vWF) - cleaving protease based on decreased collagen binding affinity of 
degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura 
(TTP). Thromb Haemost. 1999;82:1386-89. 
19. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, et al. The 
SOFA (Sepsis-related Organ Failure Assessment) score to describe organ 
dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the 
European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707-10. 
20. Muckart DJ, Bhagwanjee S. American College of Chest Physicians/Society of Critical 
Care Medicine Consensus Conference definitions of the systemic inflammatory response 
syndrome and allied disorders in relation to critically injured patients. Crit Care Med. 
1997;25:1789-95. 
21. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving 
sepsis campaign: international guidelines for management of severe sepsis and septic 
shock: 2012. Crit Care Med. 2013;41:580-637. 
22. Reiter RA, Varadi K, Turecek PL, Jilma B, Knöbl P. Changes in ADAMTS13 (von-
Willebrand-factor-cleaving protease) activity after induced release of von Willebrand 
factor during acute systemic inflammation. Thromb Haemost. 2005;93:554-8. 
23. Reiter RA, Knöbl P, Varadi K, Turecek PL. Changes in von Willebrand factor-cleaving 
protease (ADAMTS13) activity after infusion of desmopressin. Blood. 2003;101:946-8.  
24. Uemura M, Fujimura Y, Matsumoto M, , Ishizashi H, Kato S, Matsuyama T, et al.  
Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. Thromb 
Haemost. 2008;99:1019-29.  
25. Mackie I, Eapen CE, Neil D, Lawrie AS, Chitolie A, Shaw JC, Elias E.  Idiopathic 
noncirrhotic intrahepatic portal hypertension is associated with sustained ADAMTS13 
deficiency. Dig Dis Sci. 2011;56:2456-65. 
26. Goel A, Alagammai PL, Nair SC, , Mackie I, Ramakrishna B, Muliyil J, et al.  
ADAMTS13 deficiency, despite well-compensated liver functions in patients with 
noncirrhotic portal hypertension. Indian J Gastroenterol. 2014;33:355-63. 
27. Goel A, Elias JE, Eapen CE, Ramakrishna B, Elias E. Idiopathic Non-Cirrhotic 
Intrahepatic Portal Hypertension (NCIPH)-Newer Insights into Pathogenesis and 
Emerging Newer Treatment Options. J Clin Exp Hepatol. 2014;4:247-56. 
28. Chen J, Reheman A, Gushiken FC, Nolasco L, Fu X, Moake JL et al.  N-
acetylcysteine reduces the size and activity of von Willebrand factor in human plasma 
and mice. J Clin Invest. 2011;121:593-603. 
29. Lisman T, Bongers TN, Adelmeijer J, Janssen HL, de Maat MP, de Groot PG, et al. 
Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite 
reduced functional capacity. Hepatology 2006;44:53-61. 
30. Eapen CE, Elias JE, Mackie I, Elias E. Prognostic significance of von willebrand factor 
in cirrhosis: a possible mechanism. Hepatology 2013;58:1189. 
31. Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal 
vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and 
portal hypertension. Hepatology 1995;21:1238-47. 
32. George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J 
Med. 2014;371:654-66. 
33. Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic 
thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 
patients. N Engl J Med. 1991;325:398-403.   
34. Flaum MA, Cuneo RA, Appelbaum FR, Deisseroth AB, Engel WK, Gralnick HR. The 
hemostatic imbalance of plasma-exchange transfusion. Blood. 1979;54(3):694-702. 
35. Lin SM , Yeh JH, Lee CC, Chiu HC. Clearance of fibrinogen and von Willebrand factor 
in serial double-filtration plasmapheresis. J Clin Apher. 2003;18(2):6770.  
36. McLeod BC. Therapeutic apheresis: use of human serum albumin, fresh frozen plasma 
and cryosupernatant plasma in therapeutic plasma exchange. Best Pract Res Clin 
Haematol. 2006;19(1):157-67. 
37.  Dahlan R, Sontrop JM, Li L, Ghadieh O, Clark WF. Primary and Secondary Thrombotic 
Microangiopathy Referred to a Single Plasma Exchange Center for Suspected 
Thrombotic Thrombocytopenic Purpura: 2000-2011. Am J Nephrol. 2015;41:429-37.  
38. Eskazan AE, Salihoglu A. Treatment and Outcome of Primary and Secondary 
Thrombotic Microangiopathies. Am J Nephrol. 2015;41:427-8.  
39. Zheng XL, Kaufman RM, Goodnough LT, Sadler JE. Effect of plasma 
exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical 
outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic 
purpura. Blood. 2004;103:4043-9.  
40. Deepanjali S, Naik RR, Mailankody S, Kalaimani S, Kadhiravan T. Dengue Virus 
Infection Triggering Thrombotic Thrombocytopenic Purpura in Pregnancy. Am J Trop 
Med Hyg. 2015; pii: 15-0326. [Epub ahead of print] 
41. Yu JW, Sun LJ, Zhao YH, Li SC. Prediction value of model for end-stage liver disease 
scoring system on prognosis in patients with acute-on-chronic hepatitis B liver failure 
after plasma exchange and lamivudine treatment. J Gastroenterol Hepatol. 2008;23:1242-
9. 
42. Yue-Meng W, Yang LH, Yang JH, Xu Y, Yang J, Song GB. The effect of plasma 
exchange on entecavir-treated chronic hepatitis B patients with hepatic de-compensation 
and acute-on-chronic liver failure. Hepatol Int. 2015 [Epub ahead of print] 
43. Qin G, Shao JG, Wang B,  Shen Y, Zheng J, Liu XJ, et al.  Artificial liver support system 
improves short- and long-term outcomes of patients with HBV-associated acute-on-
chronic liver failure: a single-center experience. Medicine (Baltimore). 2014;93:e338. 
doi: 10.1097/MD.0000000000000338. 
44. Larsen FS, Schmidt LE, Bernsmeier C, Rasmussen A, Isoniemi H, Patel VC,et al. High-
volume plasma exchange in patients with acute liver failure: An open randomised 
controlled trial. J Hepatol. 2015. doi: 10.1016 / j.jhep.2015.08.018. [Epub ahead of print] 
45. Eapen CE, Elias E, Goel A, John TJ. Hypothesis of mechanism of thrombocytopenia in 
severe dengue, providing clues to better therapy to save lives. Current Science 
2015;108:168–9. 
46. Ko S, Chisuwa H, Matsumoto M, Fujimura Y, Okano E, Nakajima Y. Relevance of 
ADAMTS13 to liver transplantation and surgery. World J Hepatol. 2015;7:1772-81.  
47. Li GW, Rambally S, Kamboj J, , Reilly S, Moake JL, Udden MM, Mims MP. Treatment 
of refractory thrombotic thrombocytopenic purpura with N-acetylcysteine: a case report. 
Transfusion. 2014;54:1221-4. 
48. Elias JE, Mackie I, Eapen CE, Chu P, Shaw JC, Elias E. Porto-pulmonary hypertension 
exacerbated by platelet transfusion in a patient with ADAMTS13 deficiency. J Hepatol. 
2013;58:827-30.  
49. Erpenbeck L, Demers M, Zsengellér ZK, Gallant M, Cifuni SM, Stillman IE, et al.  
ADAMTS13 Endopeptidase Protects against Vascular Endothelial Growth Factor 
Inhibitor-Induced Thrombotic Microangiopathy. J Am Soc Nephrol. 2015. pii: 
ASN.2014121165. [Epub ahead of print] 
  
Table 1 : Baseline characteristics in ACLF patients  
 
Parameter 
All ACLF 
patients 
(n=50) 
Discharged 
alive 
(n=29) 
Composite 
poor 
outcome 
(n=21) 
p-value* 
Age (years) 43.5 (28-64) 43 (28-64) 40 (30-58) 0.7 
Sex (M:F) 45:5 26:3 19:2 1 
Etiology of chronic liver disease 
(Alcohol : Hepatitis B : Others) 39 : 5 : 7 22 : 4 : 3 17 : 1 : 3 - 
Acute insult (Alcohol : Viral : 
Others) 37 : 5 : 8 21 : 3 : 5 16 : 2 : 3 - 
Serum bilirubin (mg/dl) 17.3 (5-37) 11.6 (5-33.4) 
21.7 (5.1-
37) 
0.1 
Serum creatinine (mg/dl) 1.4 (1-6) 1 (1-6) 2.2 (1-6) 0.005 
Prothrombin time (INR) 2 (1.5-10) 1.9 (1.5-4.5) 2.2 (1.5-10) 0.293 
Platelet counts (x103/µL) 93 (30-353) 92 (30-240) 96 (30-353) 1 
MELD score 29 (17-49) 26 (17-49) 35 (22-47) 0.002 
SOFA score 7 (4-14) 6 (4-14) 8 (4-14) 0.007 
ACLF grading (Grade 0:1:2:3) 16:13:13:8 15:8:3:3 1:5:10:5 0.001 
SIRS, n(%) 41 (82%) 24 (83%) 17(81%) 1.000 
Sepsis, n(%) 20 (40%) 15# (52%) 5$ (24%) 0.08 
Duration of hospital stay (days) 6 (2-28) 7 (3-28) 5 (2-12) 0.08 
All continuous variables are expressed as median (range) and categorical variables as numbers 
(percentage). 
*Comparing ‘Discharged alive’ v/s ‘Composite poor outcome’  
# Either culture positive from blood (4), ascitic fluid (3), urine (2) samples; and/or neutrophilic ascitic 
fluid suggesting spontaneous bacterial peritonitis (11). 
$ Either culture positive from blood (2), ascitic fluid (2), urine(2) and/or neutrophilic ascitic fluid 
suggesting spontaneous bacterial peritonitis (3). 
MELD : model for end stage liver disease; SOFA: sequential organ failure assessment; ACLF : acute-on-
chronic liver failure; SIRS : systemic inflammatory response syndrome 
Table 2: Liver disease severity (MELD score), plasma vWF levels (on Days 1 and 3 of hospital 
stay) and in - hospital survival in patients in different grades of ACLF.  
 
 ACLF grades p 
value* 
Grade 0 
(n=16) 
Grade 1 
(n=13) 
Grade 2 
(n=13) 
Grade 3 
(n=8) 
Age ( years) 
 
41 (30-63) 49 (30-62) 41 (28-64) 40.5 (35-58) 0.75 
MELD 
 
23 (19-27) 29 (17-36) 37 (26-47) 41 (30-49) <0.001 
vWF antigen (Day 1)  
 
690 (264-
1082) 
700 (212-
1347) 
686 (515-
1338) 
986 (742-
1344) 
0.09 
vWF antigen (Day 3)  654 (301-
1169) 
640 (279-
1411) 
594 (334-
998) 
885 (702-
1054) 
0.5 
vWF activity (Day 1) 491 (97-
949) 
468 (116-
835) 
532 (221-
1090) 
882 (676-
11157) 
0.02 
vWF activity (Day 3) 
 
466 (100-
1247) 
447 (132-
1218) 
441 (277-
1304) 
766 (713-
904) 
0.16 
Platelets (x103/µL) 
 
99 (39-243) 71 (30-225) 121 (30-353) 94 (35-198) 0.9 
Composite poor 
outcome   n (%) 
1(6%) 5 (38.5%) 10 (76.9%) 5 (62.5%) 0.01 
MELD : Model for end-stage liver disease; vWF : von-Willebrand factor. 
*Univariate ordinal regression 
 
 
  
Table 3: Comparing Day 1 plasma vWF levels in 50 ACLF patients as per presence of sepsis 
and systemic inflammatory response syndrome (SIRS) at presentation and as per new onset renal 
failure or encephalopathy which developed during hospital stay. 
 
 SIRS Sepsis New onset renal failure / 
encephalopathy 
 Yes 
(n=41) 
No 
(n=9) 
p-
value 
Yes 
(n=20) 
No 
(n=30) 
p-
value 
Yes (n=9) No 
(n=41) 
p-
value 
Day 1 
vWF 
antigen 
725 
(212-
1347) 
789 
(264-
1338) 
1 696 
(260-
1249) 
779 
(212-
1347) 
0.3 955 (369-
1347) 
711 
(212-
1344) 
0.4 
Day 1 
vWF 
activity 
589 
(97-
1157) 
522 
(119-
1090) 
0.8 510 
(97-
1411) 
564 
(119-
1157) 
0.25 736 (221-
835) 
532 
(97-
1157) 
0.7 
 
  
Table 4: Plasma vWF activity on Day 1 as a predictor of in - hospital composite poor outcome 
(death/ transplant/ discharged in terminal condition) in ACLF patients  
 
 
vWF 
activity 
Composite 
poor 
outcome 
Alive 
Hazard 
ratio 
Sensitivity Specificity NPV PPV NLR PLR 
 
>250% 
19 23 
2.5 (0.5-
13.7) 
0.9      
(0.8-1) 
0.2        
(0.1-0.3) 
0.8  
(0.4-1) 
0.5  
(0.4-
0.5) 
0.46 
(0.1-
2.3) 
1.1 
(0.9-
1.3) 
 
<250% 
2 6 
 
 
>500% 
15 13 
3.1 (0.9-
10.2) 
0.7    (0.5-
0.9) 
0.5     (0.4-
0.7) 
0.7 
(0.6-
0.9) 
0.5 
(0.4-
0.7) 
0.5 
(0.2-
1.1) 
1.6 
(0.9-
2.5) 
 
<500% 
6 16 
 
 
>750% 
8 3 
5.3 (1.2-
23.5) 
0.4 (0.2-
0.5) 
0.9(0.8-1) 
0.7(0.6-
0.7) 
0.7(0.4-
0.9) 
0.7(0.5-
1) 
3.7(1-
16.6)  
<750% 
13 26 
 
 
>1000% 
5 0 
∞ (1.3-
∞) 
0.2(0.1-
0.2) 
1(0.9-1) 
0.6(0.6-
0.6) 
1(0.5-
0.9) 
0.8(0.8-
1) 
∞ 
(1.3-
∞) 
 
<1000% 
16 29 
NPV : negative predictive value, PPV : positive predictive value, NLR : negative likelihood 
ratio, PLR : positive likelihood ratio  
 
 
 
 
 
 
 
 
 
 
  
Table 5.  Plasma vWF levels as predictor of survival in different studies of patients with acute 
liver failure, ACLF and cirrhosis.  
 ACLF 
(Present 
study) 
Cirrhosis11 Cirrhosis12 Cirrhosis ± 
systemic 
inflammation14 
Acute 
liver 
failure13 
 
n 
 
      50 
 
42 
286  
80 
 
 
50 
189 (comp-
ensated) 
97 (decomp-
ensated) 
vWF 
antigen 
725% 
(212 – 
1347)% 
222 ±17 % 264% (194-
345) % 
394% (303-
505)% 
 547% 
(242-
1420)% 
Follow 
up   
8 (3-28) 
days 
24 (1-24) 
months 
33 (30-36) months 2 years  
Predicting outcome 
vWF 
antigen 
AUC: 
0.63 (95% 
CI: 0.47-
0.8) 
AUC : 
0.74* (95% 
CI: 0.58 – 
0.9) 
AUC : 0.71 
 (95% CI: 0.65-0.77)* 
AUC : 0.78#  
(95% CI: 0.66–
0.91) 
NS# 
*Predicting death / transplant / portal hypertension related event 
#Predicting transplant free survival  
AUC : area under the curve ; NS : not significant 
  
 Figure Legends : 
 
 
Figure 1 : Comparing Day 1 plasma vWF antigen and activity in ACLF patients who were 
discharged from hospital in stable state to those with composite poor outcome.  
 
 
Figure 2 : Plasma vWF antigen and activity in ACLF patients as compared to healthy volunteers 
and patients with hepatitis B/C related compensated cirrhosis. 
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